The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Abstract Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms.
Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of …

Background Patients with inflammatory bowel disease (IBD) are at higher risk for severe
COVID-19 infection. However, most studies are single-center, and nationwide data in the …

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD,
as well as the risk factors for a severe course and long-term sequelae. This is a prospective …

Lay Summary This prospective case-control study investigated the impact of severe acute
respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and …

Background Between people with and without inflammatory bowel disease (IBD), there was
no statistically significant difference in the probability of contracting the severe acute …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised
concerns in patients with inflammatory bowel disease (IBD), not only due to consequences …

Inflammatory bowel diseases (IBD), including Crohn's disease, ulcerative colitis, and
unclassified inflammatory bowel disease, are a group of chronic, immune mediated …

Abstract Background and Aims Immunosuppressed individuals are at higher risk for COVID-
19 complications, yet data in patients with inflammatory bowel disease (IBD) are limited. We …